Chief Executive Officer, Denali Therapeutics
Appears in 1 story
Leading commercial launch of AVLAYAH
For decades, the blood-brain barrier has blocked nearly all large-molecule drugs from reaching the brain — a biological wall that left most neurological diseases effectively untreatable with modern biologics. On March 25, 2026, the FDA approved Denali Therapeutics' AVLAYAH. It's the first drug specifically engineered to cross the blood-brain barrier and deliver a therapeutic enzyme to the central nervous system after a simple intravenous infusion.
Updated May 30
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
